In a drug-eluting stent, drug selection and coating integrity directly influence vascular healing and long-term vessel response. EluNIR-PERL™ integrates Ridaforolimus with an Elastomeric Coating engineered to support controlled drug release and surface integrity.
Powered by Ridaforolimus
Ridaforolimus is a non-pro-drug analog of rapamycin.
Ridaforolimus is not a prodrug; it offers more consistent and predictable drug action, which is desirable in drug-eluting stents for better safety and efficacy.
Moreover, Ridaforolimus has a broad therapeutic window. The goal of DES is inhibition of Smooth Muscle Cells (SMC) while not hindering Endothelial Cells (EC) growth.
The EC are responsible for the well-being of the blood vessels. In contrast, an accelerated growth of SMC is at the heart of the process of neo-intimal proliferation which ultimately leads to restenosis.
As demonstrated, Ridaforolimus presents a good therapeutic window as it inhibits the growth of SMC while minimally affecting the growth of EC. Thus, Ridaforolimus is an appropriate drug to use on a DES.
Ridaforolimus offers the optimal therapeutic balance, effectively inhibiting Smooth Muscle Cells proliferation while minimally inhibiting Endothelial Cells growth. It is described as an excellent choice for drug-eluting stents.
The drug elution kinetics of Ridaforolimus from an EluNIR Family is similar to the drug elution kinetics of other DES. In addition, Medinol has performed a drug deposition analysis over time. EluNIR Family has a controlled and stable release of drug into the arterial wall.
Ridaforolimus Promotes Healthy Endothelialization
EluNIR-PERL™ shows comparable or even better endothelial healing than bare-metal stents which are known for faster healing.
EluNIR-PERL™ shows complete endothelialization even at overlap zones by 30 days.
Surface of EluNIR-PERL™ shows smooth, continuous cell layer, indicating good endothelial growth.
Elastomeric Coating: Improved Surface Quality
Drug performance in a DES is closely linked to coating integrity.
Polymer coating irregularities include ridging, flaking, webbing and delamination.
The EluNIR-PERL DES has elastic properties that maintains surface integrity, providing controlled drug release.
EluNIR-PERL™ incorporates a Unique Elastomeric Coating that expands uniformly with stents..
Data on File – Elastomer: High Elasticity Polymer.
Conclusion
EluNIR-PERL™ combines Ridaforolimus and Elastomeric Coating to deliver controlled drug release, surface integrity, and support for endothelial healing.
Less Inflammation, More Healing.
